These tests are also used in prostate cancer screening, which looks for cancer before you have symptoms. If your results are abnormal, you may need more tests, such as an ultrasound, MRI, or biopsy.
Treatment often depends on the stage of the cancer. How fast the cancer grows and how different it is from surrounding tissue helps determine the stage. Men with prostate cancer have many treatment options. The treatment that's best for one man may not be best for another. The options include watchful waiting, surgery, radiation therapy, hormone therapy, and chemotherapy.
You may have a combination of treatments. NIH: National Cancer Institute MalaCards based summary : Prostate Cancer, also known as prostate carcinoma, is related to prostate disease and breast cancer , and has symptoms including tremor, angina pectoris and equilibration disorder.
The drugs Degarelix and Eligard have been mentioned in the context of this disorder. Affiliated tissues include prostate, bone and lymph node, and related phenotypes are prostate cancer and cellular Disease Ontology : 12 A male reproductive organ cancer that is located in the prostate.
Genetics Home Reference : 26 Prostate cancer is a common disease that affects men, usually in middle age or later. In this disorder, certain cells in the prostate become abnormal and multiply without control or order to form a tumor. In some aspects, the sialidase in the composition is an Actinomyces viscosus sialidase, a Clostridium perfringens sialidase, an Arthrobacter ureafaciens sialidase, a Micromonospora viridifaciens sialidase, a human Neu2 sialidase, or a human Neu4 sialidase.
In one aspect, where the sialidase of the composition is an Actinomyces viscosus sialidase, the amino acid sequence of the catalytic domain comprises the sequence of amino acids beginning at any of the amino acid residues from amino acid to amino acid and ending at any of the amino acid residues from amino acid to amino acid of the sequence of amino acids set forth in SEQ ID NO.
For example, the sequence of the catalytic domain can comprise the sequence of amino acids beginning at amino acid and ending at amino acid of the sequence of amino acids set forth in SEQ ID NO. In one aspect, where the composition comprising microparticles of a sialidase fusion protein, the anchoring domain of the sialidase fusion protein is a glycosaminoglycan GAG -binding domain.
The amount of protein in the microparticles of the compositions provided herein can vary. In one aspect, the compositions provided herein can further contain an active agent. The active agent can be a nutritional supplement, antidiabetics, anticonvulsants, analgesics, antiparkinsons, anti-inflammatories, calcium antagonists, anesthetics, antimicrobials, antimalarials, antiparasitics, antihypertensives, antihistamines, antipyretics, alpha-adrenergic agonists, alpha-blockers, biocides, bactericides, bronchial dilators, beta-adrenergic blocking drugs, contraceptives, cardiovascular drugs, calcium channel inhibitors, depressants, diagnostics, diuretics, electrolytes, enzymes, hypnotics, hormones, hypoglycemics, hyperglycemics, muscle contractants, muscle relaxants, neoplastics, glycoproteins, nucleoproteins, lipoproteins, ophthalmics, psychic energizers, sedatives, steroids, sympathomimetics, parasympathomimetics, tranquilizers, urinary tract drugs, vaccines, vaginal drugs, vitamins, minerals, nonsteroidal anti-inflammatory drugs, angiotensin converting enzymes, polynucleotides, polypeptides and polysaccharides.
The compositions provided herein can have a shelf-life of varying length. The microparticles in the compositions provided herein can further contain a counterion, such as, for example, an anion, a cation, or a zwitterion. In certain embodiments, the counterion is selected from among glycine, sodium citrate, sodium sulfate, zinc sulfate, magnesium sulfate, potassium sulfate or calcium sulfate.
The amount of counterion in a microparticle can be varied. For example, the amount of counterion in the microparticles can be from about 0. The compositions provided herein can be formulated for a variety of modes of administration. For example, the compositions can be orally e. The compositions also can formulated for pulmonary or ophthalmic administration. In a certain aspect, the composition provided herein is for inhalation.
The compositions provided herein can be formulated as tablets, caplets, gels, vials, pre-filled syringes, inhalers, electrostatic devices and other devices for delivery. The delivery dosage of the compositions can be from between about 0.
The frequency of administration of a dose, for example, for the treatment or prophylaxis of influenza, can be from three or more times a day, to two times a day, to once a day, to two times a week, to once a week, to once every two weeks or less frequent than once every two weeks.
For prophylaxis, the administration generally can be of the order of about once every two weeks or less frequent, such as once every three weeks or once every four weeks or longer.
The size of the microparticles in the compositions provided herein can vary. For example, the size of the microparticles can be from about 0. In certain embodiments, the size of the microparticles is from about 0. Also provided herein are articles of manufacture that contain a composition containing microparticles of a sialidase or a sialidase fusion protein, a packaging material for the composition and a label that indicates that the composition is for a therapeutic indication.
In one embodiment, the therapeutic indication is influenza. The article of manufacture also can contain an inhaler for pulmonary administration of the composition.
In certain embodiments, the inhaler is a dry powder inhaler, a metered dose inhaler or an electrostatic delivery device. Definitions Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which the invention s belong. All patents, patent applications, published applications and publications, Genbank sequences, websites and other published materials referred to throughout the entire disclosure herein, unless noted otherwise, are incorporated by reference in their entirety.
In the event that there are a plurality of definitions for terms herein, those in this section prevail. Where reference is made to a URL or other such identifier or address, it understood that such identifiers can change and particular information on the internet can come and go, but equivalent information can be found by searching the internet. Reference thereto evidences the availability and public dissemination of such information.
A macromolecule can be, for example, a polynucleotide, a nucleic acid molecules including DNA, RNA and peptide nucleic acid PNA a polypeptide, a protein, a carbohydrate, or a lipid, or derivatives or combinations thereof, for example, a nucleic acid molecule containing a peptide nucleic acid portion or a glycoprotein, respectively. The methods, compositions, combinations, kits and articles of manufacture provided herein, although described with reference to proteins, can be adapted for use with other macromolecules as defined and provided herein.
The active ingredient is preferably essentially uniformly dispersed, in particular homogeneously dispersed or dissolved, in the excipient matrix. A preparation preferably comprises microspheres. The preparations of the invention are distinguished in particular by high stability, a release of active ingredient which can be controlled by the particle size and composition of the matrix, good flow characteristics, good compressibility and by a uniform delivery of active ingredient. In the case of acid-labile active ingredients it is moreover possible to achieve, through choice of the matrix excipients, an acid resistance so that it is possible in the case of oral forms to dispense with an acid-resistant coating enteric coating.
In the case of active ingredients which have an unpleasant taste or, for example, show a local anesthetic effect in the mouth after administration, it has been observed that an unpleasant taste of the active ingredient can be masked, and anesthetic effects in the mouth can be avoided, by preparations of the invention. It is particularly worthy of mention that the preparations of the invention can be further processed to a large number of pharmaceutical dosage forms without thereby losing a given functionality such as taste masking, resistance to gastric juice, slowing of release.
Thus, for example, on compression of the active ingredient units of the invention no or negligible loss of functionality is observed even if deformation of the active ingredient units occurs.
In contrast to this, with conventional pellets, which normally have a functional coating such as taste masking, resistance to gastric juice, slowing of release , a certain degree of damage to the coating and thus to the functionality is observed on further processing to dosage forms, for example on compression to tablets.
This may also lead in some cases to active ingredient being released in an unwanted way. Active ingredients of the invention are, in particular, active pharmaceutical ingredients. Examples of active ingredients which may form part of the preparations of the invention are, in particular, the active pharmaceutical ingredients mentioned below: Adrenergics: apraclonidine; brimonidine; dapiprazole; deterenol; dipivefrin; dopamine; ephedrine; esproquin; etafed- rine; hydroxyamphetamine; levonordefrin; metaraminol; norepinephrine; oxidopamine; phenylpro- panolamine; prenalterol; propylhexedrine; pseudoephedrine.
Adrenocorticosteroids: ciprocinonide; desoxycorticosterone acetate; desoxycorticosterone pivalate; dexamethasone acetate; fludrocortisone acetate; flumoxonide; hydrocortisone hemisuccinate; methylprednisolone hemisucci- nate; naflocort; procinonide; timobesone acetate; tipredane. Agents to prevent alcohol abuse: disulfiram, acamprosate, milnacipran, fomepizole, lazabemide, nadide; nitrefazole; sunepitron.
Aldosterone antagonists: canrenoate; canrenone; dicirenone; mexrenoate; prorenoate; spironolactone, epostane, mespirenone; oxprenoate, spirorenone, spiroxasone, prorenone, eplerenone.
Amino acids: alanine; aspartic acid; cysteine; histidine; isoleucine; leucine; lysine; methionine; phenylalanine; pro- line; serine; threonine; tryptophan; tyrosine; valine. Active ingredients for ammonium detoxification: arginine; arginine glutamate; arginine hydrochloride; glutamic acid; Anabolics: androstanolone, bolandiol dipropionate; bolasterone; boldenone undecylenate; bolenol; bolnantalate; ethylestrenol; metenolone acetate; metenolone enanthate; bolazine; mesteronole; metandienone; nan- drolone; oxandrolone; prasterone; stanozolone; tiomesterone; clostebol; mibolerone; nandrolone cy- clotate; norbolethone; quinbolone; stenbolone acetate; tibolone; zeranol.
Analeptics: modafinil; amineptine; endomide; etamivan; fenoxypropazine; fenozolone; hexapradol; nialamide; ni- cethamide.
In one embodiment of this aspect, the resulting composition contains the microparticles containing the protein as the only active ingredient i. It also is desirable for the particles to have a protein content that is as high as possible and that maintains its activity for concentrated delivery and therapeutic efficacy. Where the protein is a sialidase fusion protein, the sialidase fusion protein can comprise a catalytic domain of a sialidase and an anchoring domain. Antidiarrheals: rolgamidine, diphenoxylate Lomotil , metronidazole Flagyl , methylprednisolone Medrol , sulfasal- azine Azulfidine.
The invention therefore relates to a preparation in which an active ingredient is essentially uniformly dispersed in an excipient matrix composed of one or more excipients selected from the group of fatty alcohol, triglyceride, partial glyceride and fatty acid ester. ACE inhibitors: alacepril; benazepril; benazeprilat; BMS ; BRL; captopril; ceronapril; CGSC; cilazapril; cilazaprilat; dehydrocaptopril; delapril; enalapril; enalaprilat; EU; EXP ; fasidotril; fosinopril; fosinoprilat; idrapril; imidapril; imidaprilat; indolaprii; libenzapril; lisinopril; mixanpril; moexipril; moexiprilat; moveltipril; omapatrilat; orbutopril; pentopril; perindopril; perindoprilat; pivopril; quinapril; quinaprilat; ramipril; rentiapril; sampatrilat; SCH; spiraprii; spiraprilat; temocapril; temocaprilat; teprotide; trandolapril; trandolaprilat; utibapril; utibaprilat; ZA; zabicipril; zofenopril; zofenoprilat. In one embodiment, the steps are performed sequentially a , b and then c.
Genetics Home Reference : 26 Prostate cancer is a common disease that affects men, usually in middle age or later. In some aspects, the methods provided herein further comprise separating the microparticles from the solution to remove components other than the microparticles. This is because it often grows very slowly so it is generally possible to treat it effectively. The frequency of administration of a dose, for example, for the treatment or prophylaxis of influenza, can be from three or more times a day, to two times a day, to once a day, to two times a week, to once a week, to once every two weeks or less frequent than once every two weeks. Bronchodilators: acefyliine; azaspirium chloride; bambuterol; bamifylline; bitoiterol; broxaterol; butaprost; carbuterol; cipamfylline; colterol; doxaprost; doxofylline; dyphylline; enprofylline; ephedrine; eprozinol; etanterol; fenspiride; flutropium bromide; formoterol; guaithylline; hexoprenaline; Hoku ; hoquizil; imoxiterol; ipragratine; ipratropium bromide; isoetharine; isoproterenol; levosalbutamol; mabuterol; mequitamium iodide; metaproterenol; mexafylline; nardeterol; nestifylline; nisbuterol; picumeterol; piquizil; pirbuterol; procaterol; reproterol; RO; quazodine; quinterenol; racepinephrine; reproterol; rimiterol; sal- butamol; salmeterol; salmeterol xinafoate; sevitropium mesilate; soterenol; sulfonterol; suloxifen; TA; theophylline; terbutaline; theophylline ethylenediamine; tiaramide; tipetropium bromide; tre- toquinol; tulobuterol; zindotrine; zinterol. Provided herein are methods of making a protein-based composition.
You may have a combination of treatments.
All patents, patent applications, published applications and publications, Genbank sequences, websites and other published materials referred to throughout the entire disclosure herein, unless noted otherwise, are incorporated by reference in their entirety. The prostate is a gland that surrounds the male urethra and helps produce semen, the fluid that carries sperm.
Anxiolytics: adatanserin; alpidem; binospirone mesilate; bretazenil; glemanserin; ipsapirone; mirisetron maleate; ocinaplon; ondansetron; panadiplon; pancopride; pazinaclone; serazapine; tandospirone citrate; zalo- spirone. However, PSA is released in increasing amounts when the prostate is malfunctioning, as is the case with prostate cancer. It is rare in men younger than The novel preparation is suitable for the production of a large number of pharmaceutical dosage forms.
Prostate cancer occurs when cells within the prostate grow uncontrollably and create small tumors. There further is a need for a method of producing microparticles that contain high concentrations of the protein or macromolecule relative to other components, that are stable and maintain their activity for long periods of time when stored at ambient temperature and that do not contain a significant amount of denatured protein. The frequency of administration of a dose, for example, for the treatment or prophylaxis of influenza, can be from three or more times a day, to two times a day, to once a day, to two times a week, to once a week, to once every two weeks or less frequent than once every two weeks. Anticholinergics: alverine citrate; anisotropine methylbromide; atropirie; atropine oxide; atropine sulfate; belladonna; benapryzine; benzetimide; benzilonium bromide; biperiden; biperiden; biperiden lactate; clidinium bromide; cyclopentolate; dexetimide; dicyclomine; dihexyverine; domazoline fumarate; elantrine; elucaine; ethybenztropine; eucatropine; glycopyrrolate; heteronium bromide; homatropine hydrobromide; homat- ropine methylbromide; hyoscyamine; hyoscyamine hydrobromide; hyoscyamine sulfate; isopropamide iodide; mepenzolate bromide; methylatropine nitrate; metoquizine; oxybutynin chloride; parapenzolate bromide; pentapiperium methylsulfate; phencarbamide; poldine methylsulfate; proglumide; propanthe- line bromide; propenzolate; scopolamine hydrobromide; tematropium methylsulfate; tiquinamide; to- fenacin; toquizine; triampyzine sulfate; trihexyphenidyl; tropicamide.
Prostate cancer is common among older men. Attorney Docket No. For example, in one embodiment, the sequence of the sialidase catalytic domain contains the sequence of amino acid residues set forth in SEQ ID NO Rickettsial diseases, e. The good news is that prostate cancer is one of the types of cancer with the best chances of recovery.
Antianemics: ancestim; diciferron; epoetin alfa; epoetin beta; epoetin epsilon; epoetin gamma; epoetin omega; ferrous sulfate, FK; folic acid; gleptoferron; glutathione monoisopropyl ester; leucovorin calcium; tu- caresol; TYB; velaresol; Antianginals: alinidine; amiodarone; amlodipine besylate; amlodipine maleate; azaclorzine; bamidipine; bertosamil; betaxolol; bertosamil; bevantolol; bimakalim; butoprozine; carvedilol; CD; CERM; cinepazet maleate; crobenetine; cyclovirubuxine-D; desocriptine; diproteverine; dopropidil; elgodipine; EMD- ; eniporide; ethacizine; fantofarone; FK; flestolol; flosatidil; flosequinan; FR ; GP ; GP ; hyperin; ipramidil; isosorbide dinitrate; ivabradine; KC; KRN ; KW; li- gustizine; linsidomine; metoprolol succinate; mibefradil; mildronate; mivazerol; molsidomine; monatepil maleate; nafagrel; NK ; OP; pirsidomine; pivazide; pranidipine; primidolol; ranolazine; SL- Provisional Application No. The novel preparation is suitable for producing a large number of pharmaceutical dosage forms. In one embodiment of this aspect, the resulting composition contains the microparticles containing the protein as the only active ingredient i. There further is a need for a method of producing microparticles that contain high concentrations of the protein or macromolecule relative to other components, that are stable and maintain their activity for long periods of time when stored at ambient temperature and that do not contain a significant amount of denatured protein. In another embodiment, the sequence of the catalytic domain comprises the sequence of amino acids beginning at amino acid and ending at amino acid of the sequence of amino acids set forth in SEQ ID NO.
For example, the size of the microparticles can be from about 0.